The DOI matches its Crossref record; 207 of the 209 references it cites were found in a registry or an index.
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Open accessAbstract
Although continuous glucose monitoring (CGM) devices are now considered the standard of care for people with type 1 diabetes mellitus, the uptake among people with type 2 diabetes mellitus (T2DM) has been slower and is focused on those receiving intensive insulin therapy. However, increasing evidence now supports the inclusion of CGM in the routine care of people with T2DM who are on basal insulin-only regimens or are managed with other medications. Expanding CGM to these groups could minimize hypoglycaemia while allowing efficient adaptation and escalation of therapies. Increasing evidence from randomized controlled trials and observational studies indicates that CGM is of clinical value in people with T2DM on non-intensive treatment regimens. If further studies confirm this finding, CGM could soon become a part of routine care for T2DM. In this Perspective we explore the potential benefits of widening the application of CGM in T2DM, along with the challenges that must be overcome for the evidence-based benefits of this technology to be delivered for all people with T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ajjan et al. 54 and Fernando et al. 55 provide strong support for expanding CGM use in noninsulin‐treated adults living with T2DM, including a proposed framework for the use of CGM throughout the natural history of T2D.”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · cited 1×
“HbA 1c is the gold standard marker for the risk of diabetes mellitus complications 7,197 but does not provide information on the frequency of hypoglycaemia, short-term glucose variability, or daily and/or weekly glycaemia patterns.”
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 4×
“HbA 1c is the gold standard marker for the risk of diabetes mellitus complications 7,197 but does not provide information on the frequency of hypoglycaemia, short-term glucose variability, or daily and/or weekly glycaemia patterns.”
Influential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“The majority of studies of CGM in T2DM have shown that the use of this technology reduces HbA 1c , which is an accepted marker of micro-vascular complications and long-term macrovascular disease 7,8,84 .”
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283 · cited 1×
“The estimated prevalence of diabetes mellitus among people aged >60 years is 22% and 19% in high-income and middle-income countries, respectively 139 .”
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 3×
“…the risk of hypo-glycaemia in T2DM and achieve a time below range in hypoglycaemia of 3.0 mmol/l (54 mg/dl) target of 1% of readings each day 40 , it is important that glycaemic variability, as measured by coefficient of variation over the observation period, remains 30% of the mean…”
InfluentialSelf-citationAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · cited 3×
“HCPs must understand better the heterogeneity of T2DM and the diversity of patient profiles 101,102 , as well as the growing pharmacy of treatment options.”
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“Continuous glucose monitoring (CGM) data provide accurate glycaemic metrics 198,199 such as time in range (TIR), a central indicator of glycaemic control 40 .”
Self-citationSevere hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“This finding is not surprising given the association between hypoglycaemia and adverse outcomes, such as hospitalization or ambulance attendance 73,74 , which is likely to be modifiable with the use of CGM to improve awareness of impending low blood levels of glucose 75 .”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412 · cited 1×
“The incidence of young-onset T2DM is growing, particularly in minority and low-income populations 154 .”
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403 · cited 1×
“Despite these evidence-based treatment strategies, the majority of people with T2DM throughout the world do not achieve the recommended HbA 1c glycaemic targets 1,10,11 .”
Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030
Bommer, C., Sagalova, V., Heesemann, E., Manne-Goehler, J., Atun, R., Bärnighausen, T., Davies, J., & Vollmer, S. (2018) · Diabetes Care · doi:10.2337/dc17-1962 · Cited by 1,130 · cited 1×
“164).”
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035 · cited 1×
“This finding is not surprising given the association between hypoglycaemia and adverse outcomes, such as hospitalization or ambulance attendance 73,74 , which is likely to be modifiable with the use of CGM to improve awareness of impending low blood levels of glucose 75 .”
Chrvala, C. A., Sherr, D., & Lipman, R. D. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2015.11.003 · Cited by 914 · cited 1×
“Pharmacotherapy in T2DM typically starts with non-insulin medications, primarily as oral therapeutics, such as metformin, sodium–glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors and injectable glucagon-like peptide 1 receptor agonists (GLP1RAs).”
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831 · cited 1×
“Fixing these gaps in our understanding (Box 1) could be facilitated by recently published international consensus recommendations on the use of CGM in prospective clinical trials and studies 159 .”
Self-citationHex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819
Economic Costs of Diabetes in the U.S. in 2022
(2023) · doi:10.2337/dci23-0085 · Cited by 808 · cited 1×
“For example, in 2022, the total burden of diabetes mellitus was estimated at US $412.9 billion, 74% of which was attributed to direct costs 165 .”
InfluentialLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“Although therapeutic inertia is a consequence of multiple factors 21,68–70 , fear of hypoglycaemia is known to slow therapy escalations 71,72 .”
Manickam, P., Mariappan, S. A., Murugesan, S. M., Hansda, S., Kaushik, A., Shinde, R., & Thipperudraswamy, S. P. (2022) · Biosensors · doi:10.3390/bios12080562 · Cited by 637 · cited 1×
“…(tasks that can, but do not necessarily, substantially improve outcomes that matter to patients), such as investigating the glycaemic patterns that characterize each person with T2DM, potentially using artificial intelligence 160 or accessing the skills of allied HCPs, such as pharmacists 161,162 .”
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 5×
“With increased use of CGM systems and increased accuracy in study situations over time, QoL was assessed as improving with CGM systems compared with SMBG in both people with T1DM and those with T2DM on intensive insulin therapy 57,78 .”
InfluentialSelf-citationPsychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551 · cited 1×
“Although therapeutic inertia is a consequence of multiple factors 21,68–70 , fear of hypoglycaemia is known to slow therapy escalations 71,72 .”
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543 · cited 2×
“…RCT, which involved 175 individuals with T2DM on basal insulin, showed that CGM can significantly reduce HbA 1c , time in hyperglycaemia (defined as >250 mg/dl (13.9 mmol/l)) and the rate of hypoglycaemia events over an 8-month period, compared with a control group using SMBG testing alone 58 .”
InfluentialLu, J., Ma, X., Zhou, J., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1131 · Cited by 517 · cited 1×
“…studies, time in range (TIR) is emerging as a relevant surrogate end point for microvascular complications, with a higher percentage of TIR being associated with decreased rates of Perspective retinopathy 85 and painful diabetic neuropathy 86 , and with preserved peripheral nerve function 87 .”
Health Literacy and Health Information Technology Adoption: The Potential for a New Digital Divide
Mackert, M., Mabry-Flynn, A., Champlin, S., Donovan, E. E., & Pounders, K. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.6349 · Cited by 503 · cited 1×
“Despite concerns among health-care providers about low health literacy of patients and poor engagement with digital health 186,187 , practical trials have shown that people with T2DM respond well to telemedicine 188 , with improvements in glycaemia and health-related QoL.”
Monnier, L., Colette, C., Dunseath, G. J., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1612 · Cited by 490
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487 · cited 1×
“Accordingly, support is growing for a more proactive approach, in which combinations of glucose-lowering agents are started immediately following initial diagnosis 108 .”
The relationships between time in range, hyperglycemia metrics, and HbA1c
Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822496 · Cited by 479
Palmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M., Craig, J. C., Maggo, J., Gray, V., De Berardis, G., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 420
Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Diabetes structured self-management education programmes: a narrative review and current innovations
Chatterjee, S., Davies, M. J., Heller, S., Speight, J., Snoek, F. J., & Khunti, K. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30239-5 · Cited by 372 · cited 1×
“These healthy behaviours can lead to improved glycaemic and psychosocial outcomes in people with T2DM 3–5 but DSMES goals are also important for optimization of pharmacological treatment strategies in T2DM 6 .”
Khunti, K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., Hammar, N., & Medina, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13088 · Cited by 367 · cited 2×
“Although therapeutic inertia is a consequence of multiple factors 21,68–70 , fear of hypoglycaemia is known to slow therapy escalations 71,72 .”
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358 · cited 1×
“Adopting CGM in this way in people with T2DM has been proposed 116 , and is also recommended in ADA guidance for technology use in diabetes mellitus 117 .”
Glucotypes reveal new patterns of glucose dysregulation
Hall, H., Perelman, D., Breschi, A., Limcaoco, P., Kellogg, R., McLaughlin, T., & Snyder, M. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2005143 · Cited by 326 · cited 1×
“HCPs must understand better the heterogeneity of T2DM and the diversity of patient profiles 101,102 , as well as the growing pharmacy of treatment options.”
Vigersky, R. A., Fonda, S. J., Chellappa, M., Walker, M. S., & Ehrhardt, N. M. (2012) · Diabetes Care · doi:10.2337/dc11-1438 · Cited by 301 · cited 1×
“In a further study, statistically significant reductions in HbA 1c achieved during a 12-week period of CGM use in people with T2DM not on intensive insulin therapy persisted for 52 weeks, despite a subsequent 40-week period using only Perspective SMBG 121 .”
Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L., & Khunti, K. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0260-x · Cited by 298 · cited 2×
“…a 1-year delay in treatment intensification in people with HbA 1c >7.5% was associated with a 67% increase in the risk of myocardial infarction, a 51% increase in the risk of stroke and a 64% increase in the risk of heart failure, compared to those who received timely treatment intensification 13 .”
InfluentialLu, J., Wang, C., Shen, Y., Chen, L., Zhang, L., Cai, J., Lu, W., Zhu, W., Hu, G., Xia, T., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1862 · Cited by 282 · cited 1×
“In terms of macrovascular outcomes, a lower percentage of TIR is associated with risk markers for vascular disease 90,91 , a high risk of all-cause and cardiovascular disease mortality 92 , as well as peripheral artery disease 93 and diabetic foot ulcers 94 .”
Nathan, D. M., Bayless, M., Cleary, P., Genuth, S., Gubitosi-Klug, R., Lachin, J. M., Lorenzi, G., Zinman, B., & for the DCCT/EDIC Research Group (2013) · Diabetes · doi:10.2337/db13-1093 · Cited by 272 · cited 1×
“The majority of studies of CGM in T2DM have shown that the use of this technology reduces HbA 1c , which is an accepted marker of micro-vascular complications and long-term macrovascular disease 7,8,84 .”
REDEEM: A pragmatic trial to reduce diabetes distress
Fisher, L., Hessler, D., Glasgow, R. E., Arean, P. A., Masharani, U., Naranjo, D., & Strycker, L. A. (2013) · Diabetes Care · doi:10.2337/dc12-2493 · Cited by 266 · cited 1×
“These healthy behaviours can lead to improved glycaemic and psychosocial outcomes in people with T2DM 3–5 but DSMES goals are also important for optimization of pharmacological treatment strategies in T2DM 6 .”
Continuous glucose monitoring systems for type 1 diabetes mellitus
Langendam, M., Luijf, Y. M., Hooft, L., DeVries, J. H., Mudde, A. H., & Scholten, R. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008101.pub2 · Cited by 262 · cited 1×
“…studies, early CGM systems in people with T1DM were found to have neither beneficial nor adverse effects on QoL outcomes compared with SMBG 76 , although it has been argued that dissatisfaction with early CGM systems was related to technical issues, including suboptimal accuracy, skin…”
Meneilly, G. S., & Tessier, D. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.1.m5 · Cited by 258
Khunti, K., Nikolajsen, A., Thorsted, B. L., Andersen, M., Davies, M. J., & Paul, S. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12626 · Cited by 256
Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus
Reach, G., Pechtner, V., Gentilella, R., Corcos, A., & Ceriello, A. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.06.003 · Cited by 251 · cited 1×
“Although therapeutic inertia is a consequence of multiple factors 21,68–70 , fear of hypoglycaemia is known to slow therapy escalations 71,72 .”
HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes
Lipska, K. J., Warton, E. M., Huang, E. S., Moffet, H. H., Inzucchi, S. E., Krumholz, H. M., & Karter, A. J. (2013) · Diabetes Care · doi:10.2337/dc13-0610 · Cited by 246
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
Eckel, R. H., Kahn, S. E., Ferrannini, E., Goldfine, A. B., Nathan, D. M., Schwartz, M. W., Smith, R. J., & Smith, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-0447 · Cited by 245 · cited 1×
“As obesity is a major factor in metabolic decompensation leading to insulin treatment 126 , CGM could potentially be used to monitor hyperglycaemia in people with T2DM on weight-loss medications, such as GLP1RAs 127,128 , during this period of weight change.”
Yoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.015 · Cited by 244
Identification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238 · cited 1×
“Although therapeutic inertia is a consequence of multiple factors 21,68–70 , fear of hypoglycaemia is known to slow therapy escalations 71,72 .”
Technology approaches to digital health literacy.
Dunn, P., & Hazzard, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.039 · Cited by 232
Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes
Lu, J., Ma, X., Shen, Y., Wu, Q., Wang, R., Zhang, L., Mo, Y., Lu, W., Zhu, W., Bao, Y., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0251 · Cited by 227 · cited 2×
“Overall, in T2DM there is a consistent association between a higher percentage of TIR and fewer macrovascular and microvascular complications 87,90,95–99 .”
Rubio-Valera, M., Pons-Vigués, M., Martínez-Andrés, M., Moreno-Peral, P., Berenguera, A., & Fernández, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089554 · Cited by 226 · cited 1×
“Ultimately, all stakeholders in the digital ecosystem must transform their way of operating 185 , but local implementation will require a proactive and innovative approach by multiple stakeholders.”
Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219 · cited 1×
“…(SMBG) using fingerstick testing is still recommended to help most people with T2DM to make Perspective decreasing as HbA 1c levels rise, such that in people with the highest HbA 1c levels (>10.2%), PPG contributes around 30% of the elevated glycaemic exposure, with PPG making up about 70% 35 .”
InfluentialYaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211 · cited 3×
“Also, PROs are rarely the focus of CGM studies as these measures are typically used as an ‘add-on’ to glycaemic outcomes, and are thus relegated to secondary or exploratory outcomes, although exceptions exist 55 .”
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1710 · Cited by 208 · cited 4×
“Many of these newer classes of drugs, such as SGLT2i and GLP1RAs, also have non-glycaemic benefits, such as reduced risk of cardiovascular disease and heart failure, as well as improved kidney outcomes, compared with sulfonylureas, which have contributed to their increased adoption.”
InfluentialKhunti, K., Ceriello, A., Cos, X., & De Block, C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.004 · Cited by 200 · cited 1×
“Despite these evidence-based treatment strategies, the majority of people with T2DM throughout the world do not achieve the recommended HbA 1c glycaemic targets 1,10,11 .”
Self-citationClinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring
Edelman, S. V., Argento, N. B., Pettus, J., & Hirsch, I. B. (2018) · Diabetes Care · doi:10.2337/dc18-1150 · Cited by 199 · cited 1×
“…values from the glucose sensor to a receiver or smartphone, whereas isCGM systems require users to scan their glucose sensor with the receiver or smartphone to get their up-to-date glucose readings and the associated trend arrows that show the direction and rate of glucose change at any point 53 .”
Frequent Hypoglycemia Among Elderly Patients With Poor Glycemic Control
Munshi, M. N. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.539 · Cited by 196 · cited 1×
“Use of blinded CGM 142 and data from retrospective insurance datasets 143 have confirmed that hypoglycaemia is frequent among older people with T2DM, aged up to 77 years, including those on non-insulin therapy, and those with high mean HbA 1c .”
Karter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. (2021) · JAMA · doi:10.1001/jama.2021.6530 · Cited by 191
Allen, N. A., Fain, J. A., Braun, B., & Chipkin, S. R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.01.006 · Cited by 182 · cited 1×
“A pivotal RCT demonstrated that blinded CGM over a single 3-day period with a follow-up review and diabetes education can lead to changes in behaviour and reduced HbA 1c in people with T2DM on suboptimal non-insulin therapy 124 .”
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes
Nair, A. T. N., Wesolowska‐Andersen, A., Brorsson, C., Rajendrakumar, A. L., Hapca, S. M., Gan, S., Dawed, A. Y., Donnelly, L. A., McCrimmon, R. J., Doney, A. S. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01790-7 · Cited by 176 · cited 2×
“The newly diagnosed person with T2DM The heterogeneity of disease in people diagnosed with T2DM is considerable 101 and can be mapped to a number of glucometric profiles, in which different measures of glycaemia identify separate clusters of T2DM disease phenotypes 101–104 .”
Su, G., Mi, S.-H., Tao, H., Li, Z., Yang, H.-X., Zheng, H., Zhou, Y., & Tian, L. (2013) · Diabetes Care · doi:10.2337/dc12-0925 · Cited by 175 · cited 1×
“…by CGM-derived metrics, has been linked as an independent risk factor to the development of cardiovascular disease over a 10-year period in people with T2DM 42 and with major adverse cardiac events in people with T2DM 43 , particularly in high-risk populations with acute coronary syndrome 44 .”
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
Hirst, J. A., Farmer, A. J., Dyar, A., Lung, T. W. C., & Stevens, R. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2856-6 · Cited by 173 · cited 1×
“Treatment with oral sulfonylurea drugs was previously indicated as a second-line therapy because of their efficacy 105 and low cost.”
Roussel, R., Riveline, J.-P., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2021) · Diabetes Care · doi:10.2337/dc20-1690 · Cited by 173
The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes
Monnier, L., Wojtusciszyn, A., Colette, C., & Owens, D. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0049 · Cited by 168 · cited 1×
“In individuals with T2DM, the risk of hypoglycaemia depends on both their daily mean blood glucose concentration 37 and their short-term glycaemic variability within each day 37–39 .”
Mayeda, L., Katz, R., Ahmad, I., Bansal, N., Batacchi, Z., Hirsch, I. B., Robinson, N., Trence, D. L., Zelnick, L., & de Boer, I. H. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000991 · Cited by 162 · cited 1×
“Overall, in T2DM there is a consistent association between a higher percentage of TIR and fewer macrovascular and microvascular complications 87,90,95–99 .”
Echouffo-Tcheugui, J. B., Zhao, S., Brock, G., Matsouaka, R. A., Kline, D., & Joseph, J. J. (2019) · Diabetes Care · doi:10.2337/dc18-1430 · Cited by 161
Xu, F., Zhao, L.-H., Su, J.-B., Chen, T., Wang, X.-Q., Chen, J.-F., Wu, G., Jin, Y., & Wang, X.-H. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-139 · Cited by 159 · cited 1×
“In cross-sectional studies in the context of microvascular disease in T2DM, CGM-defined glycaemic variability has been linked with deterioration in renal function 45 , diabetic retinopathy 46 and neuropathy 47–50 .”
Hypoglycemia in Type 2 Diabetes - More Common Than You Think: A Continuous Glucose Monitoring Study
Gehlaut, R. R., Dogbey, G. Y., Schwartz, F., Marling, C. R., & Shubrook, J. H. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815581052 · Cited by 158 · cited 1×
“Blinded CGM has revealed that approximately 50% of people with T2DM, including those on non-insulin therapy, experience frequent instances of mild or clinically significant (defined as blood glucose concentrations of 3.0 mmol/l) hypoglycaemia 125 , which are asymptomatic.”
InfluentialWada, E., Onoue, T., Kobayashi, T., Handa, T., Hayase, A., Ito, M., Furukawa, M., Okuji, T., Okada, N., Iwama, S., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001115 · Cited by 157 · cited 1×
“…in people with T2DM not on insulin therapy, include: increased hypo-glycaemic confidence, reduced diabetes mellitus distress and better overall wellbeing 79,80 , as well as improved psychological function, diabetes mellitus empowerment and greater diabetes mellitus treatment satisfaction 62,63 .”
Meneilly, G. S., & Tessier, D. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00405.x · Cited by 142 · cited 1×
“The risk of severe or fatal hypoglycaemia increases considerably in older individuals with diabetes mellitus treated with insulinotropic medications 144–146 , with higher risks of falls and fractures compared with younger individuals 147,148 .”
Gerbaud, E., Darier, R., Montaudon, M., Beauvieux, M.-C., Coffin-Boutreux, C., Coste, P., Douard, H., Ouattara, A., & Catargi, B. (2019) · Diabetes Care · doi:10.2337/dc18-2047 · Cited by 138 · cited 1×
“…by CGM-derived metrics, has been linked as an independent risk factor to the development of cardiovascular disease over a 10-year period in people with T2DM 42 and with major adverse cardiac events in people with T2DM 43 , particularly in high-risk populations with acute coronary syndrome 44 .”
Phillip, M., Bergenstal, R. M., Close, K. L., Danne, T., Garg, S. K., Heinemann, L., Hirsch, I. B., Kovatchev, B. P., Laffel, L. M., Mohan, V., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0375 · Cited by 135 · cited 1×
“CGM creates the opportunity for detailed remote consultations 201 , the value of which was demonstrated during the COVID 19 pandemic 51,52,202 .”
Self-citationReasons for not intensifying medications: differentiating “clinical inertia” from appropriate care
Safford, M. M., Shewchuk, R., Qu, H., Williams, J. H., Estrada, C. A., Ovalle, F., & Allison, J. J. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0433-8 · Cited by 132 · cited 1×
“The inadequate achievement of glycaemic goals in T2DM, particularly in the early stages of pharmacotherapy, are known to be related to non-adherence with treatment by individuals with T2DM 14 and to therapeutic inertia, defined as failure to initiate or intensify therapy in a timely manner 15–18 .”
Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
Lind, M., Imberg, H., Coleman, R. L., Nerman, O., & Holman, R. R. (2021) · Diabetes Care · doi:10.2337/dc20-2439 · Cited by 128 · cited 1×
“…glycaemic control that starts at the time of diagnosis of T2DM, is associated with sustained reductions in risk of myocardial infarction and death from any cause, compared to a comparator group on conventional treatment, in addition to reductions in the risk of microvascular disease 8,12 .”
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity · doi:10.1002/oby.23673 · Cited by 124
Clinical inertia—time to reappraise the terminology?
Khunti, K., & Davies, M. J. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2017.01.007 · Cited by 121
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118 · cited 1×
“…of real-world studies have shown that the use of CGM in non-insulin-treated T2DM can significantly reduce HbA 1c compared with SMBG 61–63, 109, 110 , and this Given current evidence, the intermittent use of CGM can be a viable option at 3-monthly intervals (Table 2) or during treatment change…”
Taylor, P. J., Thompson, C. H., & Brinkworth, G. D. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12807 · Cited by 115 · cited 1×
“A systematic review of 11 studies involving 5,542 participants, 90% not on intensive insulin therapy, found that intermittent use of CGM, compared with SMBG, was associated with reductions in HbA 1c and body weight, as well as improved adherence to dietary plans and physical activity 118 .”
Wright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0069 · Cited by 115 · cited 2×
“…1) and a number of real-world studies have shown that the use of CGM in non-insulin-treated T2DM can significantly reduce HbA 1c compared with SMBG 61–63, 109, 110 , and this Given current evidence, the intermittent use of CGM can be a viable option at 3-monthly intervals (Table 2) or during…”
Users’ acceptability of a mobile application for persons with type 2 diabetes: a qualitative study
Torbjørnsen, A., Ribu, L., Rønnevig, M., Grøttland, A., & Helseth, S. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4486-2 · Cited by 114
Bergenstal, R. M., Layne, J. E., Zisser, H., Gabbay, R. A., Barleen, N. A., Lee, A. A., Majithia, A. R., Parkin, C. G., & Dixon, R. F. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0396 · Cited by 114 · cited 1×
“…people with type 2 diabetes mellitus (T2DM) using CGM have been tested in real-life settings; for example the Onduo Virtual Diabetes Clinic 188,203,204 , which is associated with a statistically significant improvement in HbA 1c and with reduced diabetes mellitus distress, compared with standard…”
Doyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., & Trujillo, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2470 · Cited by 111 · cited 2×
“Although guidelines for T2DM recommend a change of therapy if HbA 1c targets are not met or if HbA 1c is not stable after 3–6 months 19,20 , the observed times to treatment intensification reported across international studies are measured in years rather than months 21 .”
Wallander, M., Axelsson, K. F., Nilsson, A. G., Lundh, D., & Lorentzon, M. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3002 · Cited by 108 · cited 1×
“The risk of severe or fatal hypoglycaemia increases considerably in older individuals with diabetes mellitus treated with insulinotropic medications 144–146 , with higher risks of falls and fractures compared with younger individuals 147,148 .”
Yoo, J. H., Choi, M. S., Ahn, J., Park, S. W., Kim, Y., Hur, K. Y., Jin, S., Kim, G., & Kim, J. H. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0499 · Cited by 107 · cited 1×
“Overall, in T2DM there is a consistent association between a higher percentage of TIR and fewer macrovascular and microvascular complications 87,90,95–99 .”
Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2013) · Diabetes Care · doi:10.2337/dc12-2127 · Cited by 104 · cited 1×
“In people with T2DM, the dawn phenomenon is estimated to contribute 0.4% to HbA 1c levels 31 and is an early manifestation of dysglycaemia in T2DM, even when HbA 1c and PPG levels are within normal ranges 33 .”
InfluentialTang, X., Li, S., Wang, Y., Wang, M., Yin, Q., Mu, P., Lin, S., Qian, X., Ye, X., & Chen, Y. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.08.004 · Cited by 100 · cited 1×
“…by CGM-derived metrics, has been linked as an independent risk factor to the development of cardiovascular disease over a 10-year period in people with T2DM 42 and with major adverse cardiac events in people with T2DM 43 , particularly in high-risk populations with acute coronary syndrome 44 .”
Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0951-8 · Cited by 99
Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts
Monnier, L., Colette, C., & Owens, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0239 · Cited by 96 · cited 1×
“…2007 that using CGM in people with T2DM reveals critical abnormalities in glycaemic homeostasis, including the early-morning hormone-induced spikes in blood levels of glucose known as the dawn phenomenon, high postprandial glycaemic excursions and extensive short-term glycaemic variability 27–32 .”
Bergenstal, R. M., Kerr, M. S. D., Roberts, G. J., Souto, D., Nabutovsky, Y., & Hirsch, I. B. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab013 · Cited by 96
Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease
Klupa, T., Czupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Gumprecht, J., Myśliwiec, M., Szadkowska, A., Bomba-Opon, D. A., Czajkowski, K., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01431-3 · Cited by 94
Schütt, M., Fach, E.-M., Seufert, J., Kerner, W., Lang, W., Zeyfang, A., Welp, R., Holl, R. W., & for the DPV Initiative and the German BMBF Competence Network Diabetes Mellitus (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03681.x · Cited by 90
Self-citationKröger, J., Fasching, P., & Hanaire, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00741-9 · Cited by 90
Gilbert, T. R., Noar, A., Blalock, O., & Polonsky, W. H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0666 · Cited by 90
Monnier, L., Colette, C., & Owens, D. R. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.962 · Cited by 89
Lu, J., Ma, X., Zhang, L., Mo, Y., Ying, L., Lu, W., Zhu, W., Bao, Y., & Zhou, J. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12957 · Cited by 88
Guerci, B., Roussel, R., Levrat‐Guillen, F., Detournay, B., Vicaut, É., de Pouvourville, G., Emery, C., & Riveline, J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0271 · Cited by 84
Cox, D. J., Banton, T., Moncrief, M., Conaway, M., Diamond, A., & McCall, A. L. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa118 · Cited by 82 · cited 3×
“…in people with T2DM not on insulin therapy, include: increased hypo-glycaemic confidence, reduced diabetes mellitus distress and better overall wellbeing 79,80 , as well as improved psychological function, diabetes mellitus empowerment and greater diabetes mellitus treatment satisfaction 62,63 .”
Aleppo, G., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1304 · Cited by 82 · cited 1×
“These reductions are achieved early, within 3–6 months of starting CGM, with the benefits reversed if CGM is discontinued 64 .”
The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes
Fonda, S. J., Graham, C., Munakata, J., Powers, J. M., Price, D., & Vigersky, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816628547 · Cited by 81 · cited 3×
“One study examined the costs for people with T2DM treated with basal insulin only, without prandial insulin, with intermittent use of CGM in four cycles (2 weeks on and 1 week off) for 3 months, followed up to 52 weeks, compared with a control group using SMBG 132 .”
InfluentialBao, S., Bailey, R., Calhoun, P., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0494 · Cited by 81
Guo, Q., Zang, P., Xu, S.-Y., Song, W., Zhang, Z., Liu, C., Guo, Z., Chen, J., Lu, B., Gu, P., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/5817074 · Cited by 80
Price, D. A., Deng, Q., Kipnes, M., & Beck, S. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01086-y · Cited by 77
Carlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S. A., French, E. K., Kruger, D. F., Miller, E. M., Özer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 77 · cited 1×
“These data are consistent with results of retrospective studies demonstrating significant reductions in HbA 1c in people with T2DM on basal insulin therapy 59,60 .”
The Impact of Real-Time Continuous Glucose Monitoring in Patients 65 Years and Older
Polonsky, W. H., Peters, A. L., & Hessler, D. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816643542 · Cited by 73 · cited 1×
“CGM, compared with standard care 81 , and individuals >65 years old on insulin therapy have reported improved sleep quality and a sense of security after starting CGM compared with SMBG 82 , as well as improved wellbeing and reduced diabetes mellitus distress compared with standard care 83 .”
Continuous Glucose Monitoring and Physical Activity
Schubert-Olesen, O., Kröger, J., Siegmund, T., Thurm, U., & Halle, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912296 · Cited by 72
The Diabetes Research in Children Network (DirecNet) Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1929 · Cited by 71
Mateo, J. F., Gil-Guillén, V. F., Mateo, E., Orozco‐Beltrán, D., Herencia, J. A. C., & Merino, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00799.x · Cited by 70 · cited 1×
“The inadequate achievement of glycaemic goals in T2DM, particularly in the early stages of pharmacotherapy, are known to be related to non-adherence with treatment by individuals with T2DM 14 and to therapeutic inertia, defined as failure to initiate or intensify therapy in a timely manner 15–18 .”
Li, F., Zhang, Y., Li, H., Lu, J., Jiang, L., Vigersky, R. A., Zhou, J., Wang, C., Bao, Y., & Jia, W. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108289 · Cited by 69 · cited 2×
“…studies, time in range (TIR) is emerging as a relevant surrogate end point for microvascular complications, with a higher percentage of TIR being associated with decreased rates of Perspective retinopathy 85 and painful diabetic neuropathy 86 , and with preserved peripheral nerve function 87 .”
Yang, J., Yang, X., Zhao, D., Wang, X., Wei, W., & Yuan, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13394 · Cited by 69
Moon, S. J., Kim, K., Lee, W. J., Lee, M. Y., Vigersky, R., & Park, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14852 · Cited by 69 · cited 2×
“Indeed, compared to SMBG, periodic use of CGM in non-insulin-treated people with T2DM has demonstrated a positive effect on glycaemic control, including reduced HbA 1c 119 and improved TIR 120 .”
Grace, T., & Salyer, J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0212 · Cited by 64 · cited 1×
“…a number of real-world studies have shown that the use of CGM in non-insulin-treated T2DM can significantly reduce HbA 1c compared with SMBG 61–63, 109, 110 , and this Given current evidence, the intermittent use of CGM can be a viable option at 3-monthly intervals (Table 2) or during treatment…”
Riveline, J.-P., Roussel, R., Vicaut, E., de Pouvourville, G., Detournay, B., Emery, C., Levrat-Guillen, F., & Guerci, B. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0085 · Cited by 64
Stedman, M., Lunt, M., Davies, M., Livingston, M. A., Duff, C. J., Fryer, A. A., Anderson, S. G., Gadsby, R., Gibson, M., Rayman, G. A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033231 · Cited by 63 · cited 1×
“The frequency of hospital admissions for diabetes mellitus-related acute events and long-term complications is also a driver for increased costs in T2DM 168,169 .”
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 63 · cited 1×
“Along with confronting therapeutic inertia, the clinical need is to assertively target hypergly-caemia early after diagnosis 157,158 and to empower people with T2DM to take more control over their condition, guided by CGM-derived glucose readings, trend arrows and daily patterns.”
Self-citationMajithia, A. R., Kusiak, C. M., Lee, A. A., Colangelo, F. R., Romanelli, R. J., Robertson, S., Miller, D. P., Erani, D. M., Layne, J. E., Dixon, R. F., et al. (2020) · Journal of Medical Internet Research · doi:10.2196/21778 · Cited by 62 · cited 1×
“…of people with type 2 diabetes mellitus (T2DM) using CGM have been tested in real-life settings; for example the Onduo Virtual Diabetes Clinic 188,203,204 , which is associated with a statistically significant improvement in HbA 1c and with reduced diabetes mellitus distress, compared with…”
Lee, J. Y., Chan, C. K. Y., Chua, S. S., Paraidathathu, T., Lee, K. K.-C., Tan, C. S. S., Nasir, N., & Lee, S. W. H. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026575 · Cited by 60 · cited 1×
“People with T2DM often prefer face-to-face consultations, since they perceive information to be clearer in this context 189,190 .”
Elliott, T., Beca, S. G., Beharry, R., Tsoukas, M. A., ZARRUK, A. R., & Abitbol, A. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211021374 · Cited by 60 · cited 1×
“These data are consistent with results of retrospective studies demonstrating significant reductions in HbA 1c in people with T2DM on basal insulin therapy 59,60 .”
Schön, M., Prystupa, K., Mori, T., Zaharia, O. P., Bódis, K., Bombrich, M., Möser, C., Yurchenko, I., Kupriyanova, Y., Strassburger, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00329-7 · Cited by 58
Hu, Y.-M., Zhao, L.-H., Zhang, X.-L., Cai, H.-L., Huang, H.-Y., Xu, F., Chen, T., Wang, X.-Q., Guo, A.-S., Li, J.-A., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1546-z · Cited by 57
Coutureau, C., Slimano, F., Mongaret, C., & Kanagaratnam, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063156 · Cited by 55 · cited 1×
“…(tasks that can, but do not necessarily, substantially improve outcomes that matter to patients), such as investigating the glycaemic patterns that characterize each person with T2DM, potentially using artificial intelligence 160 or accessing the skills of allied HCPs, such as pharmacists 161,162 .”
Danne, T., Limbert, C., Puig‐Domingo, M., Prato, S. D., Renard, É., Choudhary, P., & Seibold, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01114-x · Cited by 54 · cited 3×
“This paradigm shift will emphasize the available digital health tools and the role of telemedicine in diabetes mellitus care, which began on a large scale during the COVID-19 pandemic 51,52 .”
Bain, S. C., Bekker Hansen, B., Hunt, B., Chubb, B., & Valentine, W. J. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2019.1645018 · Cited by 53 · cited 1×
“From a health outcomes standpoint, such delayed treatment intensification is linked to a high incidence both of microvascular and macrovascular disease in T2DM 13,22 , as well as substantially increased direct and indirect costs of diabetes mellitus complications 23,24 .”
Wakasugi, S., Mita, T., Katakami, N., Okada, Y., Yoshii, H., Osonoi, T., Nishida, K., Shiraiwa, T., Torimoto, K., Kurozumi, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001923 · Cited by 53
Polonsky, W. H., Fisher, L., Hessler, D., & Edelman, S. V. (2013) · Diabetic Medicine · doi:10.1111/dme.12275 · Cited by 52
Polonsky, W. H., Layne, J. E., Parkin, C. G., Kusiak, C. M., Barleen, N. A., MILLER, D. P., Zisser, H., & Dixon, R. F. (2020) · Clinical Diabetes · doi:10.2337/cd19-0105 · Cited by 52 · cited 3×
“Despite concerns among health-care providers about low health literacy of patients and poor engagement with digital health 186,187 , practical trials have shown that people with T2DM respond well to telemedicine 188 , with improvements in glycaemia and health-related QoL.”
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 49 · cited 1×
“Along with confronting therapeutic inertia, the clinical need is to assertively target hypergly-caemia early after diagnosis 157,158 and to empower people with T2DM to take more control over their condition, guided by CGM-derived glucose readings, trend arrows and daily patterns.”
Self-citationFlash CGM associated with event reduction in nonintensive diabetes therapy
(2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88780 · Cited by 49 · cited 1×
“Notably, the use of CGM in people with T2DM on basal insulin therapy or non-insulin therapies is also associated with statistically significant reductions in clinical outcomes such as hospitalization for diabetic ketoacidosis or severe hypoglycaemia 65,66 .”
Assaf, S. A., Zelkó, R., & Hankó, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19106188 · Cited by 48
Powers, M. A., Bardsley, J. K., Cypress, M., Funnell, M. M., Harms, D., Fischl, A. H., Hooks, B., Isaacs, D. M., Mandel, E. D., Maryniuk, M. D., et al. (2020) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2020.04.020 · Cited by 47
Choudhary, P., Bellido, V., Graner, M., Altpeter, B., Cicchetti, A., Durand‐Zaleski, I., & Kristensen, F. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01132-9 · Cited by 47 · cited 2×
“This paradigm shift will emphasize the available digital health tools and the role of telemedicine in diabetes mellitus care, which began on a large scale during the COVID-19 pandemic 51,52 .”
Ward, J. E. F., Stetson, B. A., & Mokshagundam, S. P. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0172-z · Cited by 46 · cited 1×
“However, many people with T2DM experience difficulty integrating SMBG into their daily life with T2DM, for reasons related to the physical and psychological burden of SMBG testing 25,26 .”
Nyiraty, S., Pesei, F., Orosz, A., Coluzzi, S., Vági, O. E., Lengyel, C., Ábrahám, G., Frontoni, S., Kempler, P., & Várkonyi, T. T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00174 · Cited by 46
Nordyke, R. J., Appelbaum, K. J., & Berman, M. A. (2019) · Journal of Medical Internet Research · doi:10.2196/15814 · Cited by 45 · cited 1×
“The effect of wider medication deprescribing in older populations has been shown to be cost-effective 152,153 , supporting the possibility of a similar strategy in older people with T2DM.”
Ajjan, R. A., Heller, S. R., Everett, C. C., Vargas-Palacios, A., Higham, R., Sharples, L., Gorog, D. A., Rogers, A., Reynolds, C., Fernandez, C., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1219 · Cited by 44
Self-citationCOVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way
Danne, T., & Limbert, C. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30155-8 · Cited by 43 · cited 1×
“CGM creates the opportunity for detailed remote consultations 201 , the value of which was demonstrated during the COVID 19 pandemic 51,52,202 .”
Isitt, J. J., Roze, S., Sharland, H., Cogswell, G., Alshannaq, H. A., Norman, G. J., & Lynch, P. M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01324-x · Cited by 41
Guerci, B., Levrat‐Guillen, F., Vicaut, É., de Pouvourville, G., Detournay, B., Emery, C., & Riveline, J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0034 · Cited by 41
Intermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM
Ziegler, R., Heinemann, L., Freckmann, G., Schnell, O., Hinzmann, R., & Kulzer, B. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820905577 · Cited by 40 · cited 1×
“Adopting CGM in this way in people with T2DM has been proposed 116 , and is also recommended in ADA guidance for technology use in diabetes mellitus 117 .”
Romano, S., Figueira, D. C. M., Teixeira, I., & Perelman, J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01120-8 · Cited by 40 · cited 1×
“The effect of wider medication deprescribing in older populations has been shown to be cost-effective 152,153 , supporting the possibility of a similar strategy in older people with T2DM.”
Chesser, H., Srinivasan, S., Puckett, C., Gitelman, S. E., & Wong, J. C. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221139873 · Cited by 40 · cited 2×
“CGM, compared with standard care 81 , and individuals >65 years old on insulin therapy have reported improved sleep quality and a sense of security after starting CGM compared with SMBG 82 , as well as improved wellbeing and reduced diabetes mellitus distress compared with standard care 83 .”
Sierra, J. A., Shah, M., Gill, M. S., Flores, Z., Chawla, H., Kaufman, F. R., & Vigersky, R. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2017.1390474 · Cited by 38 · cited 2×
“People with T2DM using professional CGM while changing their T2DM treatment regimen saw a significant fall in their annual costs 175 .”
Rodríguez‐Fortúnez, P., Franch‐Nadal, J., Fornos-Pérez, J. A., Martínez‐Martínez, F., de Paz, H. D., & Peña, M. L. O. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028467 · Cited by 37
Giunti, G., Fernández, E., Belani, H., & Lacalle-Remigio, J. R. (2019) · Journal of Medical Internet Research · doi:10.2196/14086 · Cited by 36 · cited 1×
“A 2019 survey of 302 medical schools across EU member states 180 concluded that less than 30% of medical schools offered eHealth courses and these were mandatory in only 19%.”
Bansal, M., Shah, M., Reilly, B., Willman, S., Gill, M., & KAUFMAN, F. R. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-018-0398-2 · Cited by 35 · cited 1×
“Suboptimally controlled HbA 1c is known to be associated with increased costs of care in T2DM, as individuals with suboptimal glucose control use more health-care resources than those with optimized control 167,168 .”
Volčanšek, Š., Lunder, M., & Janež, A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0131 · Cited by 33 · cited 1×
“CGM, compared with standard care 81 , and individuals >65 years old on insulin therapy have reported improved sleep quality and a sense of security after starting CGM compared with SMBG 82 , as well as improved wellbeing and reduced diabetes mellitus distress compared with standard care 83 .”
Xie, P., Deng, B., Zhang, X., Li, Y., Du, C., Rui, S., Deng, W., Boey, J., Armstrong, D. G., Ma, Y., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3498 · Cited by 33 · cited 1×
“In terms of macrovascular outcomes, a lower percentage of TIR is associated with risk markers for vascular disease 90,91 , a high risk of all-cause and cardiovascular disease mortality 92 , as well as peripheral artery disease 93 and diabetic foot ulcers 94 .”
Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.03.012 · Cited by 32
Kim, M. Y., Kim, G., Park, J. Y., Choi, M. S., Jun, J. E., Lee, Y., Jin, S., Hur, K. Y., & Kim, J. H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0599 · Cited by 32
JENDLE, J. H., Eeg‐Olofsson, K., Svensson, J., Franzén, S., Lamotte, M., & Levrat‐Guillen, F. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01172-1 · Cited by 31 · cited 6×
“Use of isCGM improved quality-adjusted life years (QALYs), a measure of the quality and length of life for an individual, in people with T2DM on intensive insulin therapy, leading to a favourable incremental cost-effectiveness ratio (ICER) 137,138,170,171 .”
InfluentialUemura, F., Okada, Y., Torimoto, K., & Tanaka, Y. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0306 · Cited by 30
Nusca, A., Pantano, A. L., Melfi, R., Proscia, C., Maddaloni, E., Contuzzi, R., Mangiacapra, F., Palermo, A., Manfrini, S., Pozzilli, P., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2015/250201 · Cited by 29 · cited 1×
“In cross-sectional studies in the context of microvascular disease in T2DM, CGM-defined glycaemic variability has been linked with deterioration in renal function 45 , diabetic retinopathy 46 and neuropathy 47–50 .”
The Treat-to-Target Trial and Related Studies
Riddle, M. C. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.71 · Cited by 29 · cited 1×
“PPG contributes approximately 1% of the overall hyperglycaemia measured by an HbA 1c test result in people with T2DM, regardless of their total HbA 1c level 36 .”
Bouillet, B., Tscherter, P., Vaillard, L., Nonciaux, C., Hourdain, P., Ravier, A., Rouland, A., Petit, J. M., Vergès, B., & Quilot, E. (2021) · Age and Ageing · doi:10.1093/ageing/afab128 · Cited by 29 · cited 1×
“…and titration of basal insulin therapy can be associated with episodes of problematic hypoglycaemia, particularly in older people (who can be more frail) 129 , which is a common reason for discontinuation of this therapy or for reluctance of HCPs to adjust the basal insulin dose upwards 130,131 .”
The dawn phenomenon in type 2 diabetes: How to assess it in clinical practice?
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.002 · Cited by 27 · cited 1×
“The dawn phenomenon is a consequence of hepatic glucose production overnight that reaches a peak towards the end of an overnight fast 28 .”
Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care
Harris, S. B., Young, A., Davies, M. J., Gerstein, H. C., Green, J., & SKOLNIK, N. (2020) · ADA Clinical Compendia · doi:10.2337/db2020-02 · Cited by 27 · cited 1×
“The multiplicity of choices can lead to ‘decision paralysis’ 177 , resulting in reluctance to prescribe medications, even if most appropriate for the patient.”
Isaacson, B., Kaufusi, S., Sorensen, J., Joy, E. A., Jones, C., Ingram, V., Mark, N., Phillips, M., & Briesacher, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820955228 · Cited by 26 · cited 1×
“Savings were not universal and depended on the health insurance provider 176 .”
Guo, Q., Lu, B., Guo, Z., Feng, Z., Yuan, Y., Jin, X., Zang, P., Gu, P., & Shao, J. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i11.489 · Cited by 26
Mattishent, K., Richardson, K., Dhatariya, K., Savva, G. M., Fox, C., & Loke, Y. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13769 · Cited by 25 · cited 3×
“In this context, deprescribing sulfonylureas is a clear recommendation 148,149 in older people with T2DM, particularly in the presence of comorbidities.”
Short-term use of CGM in youth onset type 2 diabetes is associated with behavioral modifications
Manfredo, J., Lin, T., Gupta, R., Abiola, K., West, M., Busin, K., Tracey, J., Brown, E. A., Magge, S. N., & Wolf, R. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182260 · Cited by 25 · cited 1×
“These studies indicated that features of CGM technology, such as visible glucose readings and trend arrows, do influence changes in diabetes mellitus self-management behaviours among these groups 155 , including improved adherence with insulin treatment and avoidance of high-sugar foods.”
Bilir, S. P., Hellmund, R., Wehler, E., Li, H., Munakata, J., & Lamotte, M. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.2.80 · Cited by 24 · cited 3×
“Four studies across a range of health-care economies have found that the use of isCGM in people with T2DM on MDI or CSII therapy is considered cost-effective compared with standard care with SMBG, based on a 40-year horizon 137,138,170,171 .”
Li, J., Li, Y., Ma, W., Liu, Y., Yin, X., Xie, C., Bai, J., & Zhang, M. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.028 · Cited by 23 · cited 1×
“In terms of macrovascular outcomes, a lower percentage of TIR is associated with risk markers for vascular disease 90,91 , a high risk of all-cause and cardiovascular disease mortality 92 , as well as peripheral artery disease 93 and diabetic foot ulcers 94 .”
2016 Health Care & Education Presidential Address: If DSME Were a Pill, Would You Prescribe It?
Powers, M. A. (2016) · Diabetes Care · doi:10.2337/dc16-2085 · Cited by 22 · cited 1×
“These healthy behaviours can lead to improved glycaemic and psychosocial outcomes in people with T2DM 3–5 but DSMES goals are also important for optimization of pharmacological treatment strategies in T2DM 6 .”
Glucose Patterns in Very Old Adults: A Pilot Study in a Community-Based Population
Selvin, E., Wang, D., Tang, O., Minotti, M., Echouffo-Tcheugui, J. B., & Coresh, J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0156 · Cited by 22 · cited 1×
“As the feasibility and acceptability of CGM in very old adults up to 91 years of age has also been demonstrated 151 , the case for wider CGM access in those with T2DM is clear (Table 2).”
Pan, J., Yan, X., Li, F., Zhang, Y., Jiang, L., & Wang, C. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13652 · Cited by 22
Fernández‐Rodríguez, R., Zhao, L., Bizzozero‐Peroni, B., Martínez‐Vizcaíno, V., Mesas, A. E., Wittert, G., & Heilbronn, L. K. (2023) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2023.0374 · Cited by 22 · cited 1×
“Certainly, use of telemedicine and digital health tools can lead to reduced diabetes distress in adults with T2DM 193 .”
Meng, J., Casciano, R., Lee, Y., Stern, L. S., Gultyaev, D., Tong, L., & Kitio-Dschassi, B. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.4.446 · Cited by 21 · cited 2×
“Suboptimally controlled HbA 1c is known to be associated with increased costs of care in T2DM, as individuals with suboptimal glucose control use more health-care resources than those with optimized control 167,168 .”
Pogorzelska, K., Marcinowicz, L., & Chlabicz, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20031963 · Cited by 21 · cited 1×
“A small number of studies have also indicated that primary care teams and patients have embraced telemedicine as a consequence of the pandemic 183,184 .”
Pearson, S. M., Whittam, B., Kulavarasalingam, K., Mitchell-Gears, A., James, C., & Ajjan, R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01204-3 · Cited by 20 · cited 1×
“This finding is not surprising given the association between hypoglycaemia and adverse outcomes, such as hospitalization or ambulance attendance 73,74 , which is likely to be modifiable with the use of CGM to improve awareness of impending low blood levels of glucose 75 .”
Self-citationPowers, M. A., Bardsley, J. K., Cypress, M., Funnell, M. M., Harms, D., Fischl, A. H., Hooks, B., Isaacs, D. M., Mandel, E. D., Maryniuk, M. D., et al. (2020) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000473 · Cited by 19
Poitras, M.-È., Poirier, M.-D., Couturier, Y., Vaillancourt, V. T., Cormier, C., Gauthier, G., Massé, S., Gendron, A., Oswick, M. L., Morin, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066871 · Cited by 19 · cited 1×
“A small number of studies have also indicated that primary care teams and patients have embraced telemedicine as a consequence of the pandemic 183,184 .”
Alshannaq, H. A., Isitt, J. J., Pollock, R. F., Norman, G. J., Cogswell, G., Lynch, P. M., & Roze, S. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0075 · Cited by 19 · cited 2×
“…three national health-care settings showed that using rtCGM in people with T2DM on either MDI or basal insulin therapy is associated with increased QALYs and improved ICER over a lifetime horizon compared with SMBG, based only on direct health-care costs in the UK 172 , Canada 173 or France 174 .”
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Dashora, U. K., Sinha, S., Seidu, S., Patel, D., Beba, H., & Strain, W. D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01242-y · Cited by 18 · cited 1×
“This decision paralysis has been suggested to be a factor in the low prescription of SGLT2i by primary care physicians 178 , despite the high efficacy of these drugs.”
Self-citationHbA1c variability and diabetes complications: assessment and implications
Monnier, L., Colette, C., Bonnet, F., Renard, É., & Owens, D. R. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101399 · Cited by 18 · cited 1×
“Analysis has shown that a coefficient of variation in HbA 1c greater than 5% is indicative of an increased risk of microvascular and macrovascular complications of diabetes mellitus 122 .”
Therapeutic inertia amongst general practitioners with interest in diabetes
Seidu, S., Than, T., Kar, D., Lamba, A., Brown, P., Zafar, A., Hussain, R., Amjad, A., Capehorn, M., Martin, E., et al. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2017.09.001 · Cited by 17
Self-citationvan der Heide, F. C. T., Foreman, Y. D., Franken, I., Henry, R. M. A., Kroon, A. A., Dagnelie, P. C., Eussen, S. J. P. M., Berendschot, T. T. J. M., Schouten, J., Webers, C. A. B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22748-2 · Cited by 17 · cited 1×
“Both intraday glycaemic variability and time in hypoglycaemia have been associated with retinal nerve fibre thinning in retinopathy and neuropathy in T2DM 88,89 , and glycaemic variability has also been associated with cardiovascular autonomic neuropathy 50 .”
Gad, H., Elgassim, E., Mohammed, I., Alhaddad, A. Y., Aly, H., Cabibihan, J., Al-Ali, A. K., Sadasivuni, K. K., Petropoulos, I. N., Ponirakis, G., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110670 · Cited by 17 · cited 2×
“Both intraday glycaemic variability and time in hypoglycaemia have been associated with retinal nerve fibre thinning in retinopathy and neuropathy in T2DM 88,89 , and glycaemic variability has also been associated with cardiovascular autonomic neuropathy 50 .”
Kosjerina, V., Carstensen, B., Jørgensen, M. E., Brock, B., Christensen, H. R., Rungby, J., & Andersen, G. S. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00170-7 · Cited by 16 · cited 9×
“Such a plan would improve QoL, reduce hyperglycaemia and reduce the risk of diabetes mellitus-related complications, which are preventable with good glycaemic management.”
InfluentialGad, H., Elgassim, E., Mohammed, I., Alhaddad, A. Y., Aly, H., Cabibihan, J., Al-Ali, A. K., Sadasivuni, K. K., Haji, A., Lamine, N., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0352 · Cited by 16 · cited 1×
“Both intraday glycaemic variability and time in hypoglycaemia have been associated with retinal nerve fibre thinning in retinopathy and neuropathy in T2DM 88,89 , and glycaemic variability has also been associated with cardiovascular autonomic neuropathy 50 .”
Zhou, H., Wang, W., Shen, Q., Feng, Z., Zhang, Z., Lei, H., Yang, X., Liu, J., Lü, B., Shao, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1014568 · Cited by 16 · cited 1×
“In terms of macrovascular outcomes, a lower percentage of TIR is associated with risk markers for vascular disease 90,91 , a high risk of all-cause and cardiovascular disease mortality 92 , as well as peripheral artery disease 93 and diabetic foot ulcers 94 .”
Bahia, L., Mello, K. F., de Lemos, L. L. P., Costa, N. L., Mulinari, E., & Malerbi, D. A. C. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01208-5 · Cited by 16 · cited 3×
“Four studies across a range of health-care economies have found that the use of isCGM in people with T2DM on MDI or CSII therapy is considered cost-effective compared with standard care with SMBG, based on a 40-year horizon 137,138,170,171 .”
Buysse, H. E. C., Coremans, P., Pouwer, F., & Ruige, J. B. (2019) · Health Informatics Journal · doi:10.1177/1460458219844369 · Cited by 15 · cited 2×
“People with T2DM often prefer face-to-face consultations, since they perceive information to be clearer in this context 189,190 .”
Harris, S. B., & Levrat‐Guillen, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15025 · Cited by 15
IDRIS, I. R., Gulati, K., Perez‐Nieves, M., Hadjiyianni, I., Cao, D., Tahbaz, A., Ivanova, J. I., & Hassan, S. W. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.09.002 · Cited by 14 · cited 1×
“…and titration of basal insulin therapy can be associated with episodes of problematic hypoglycaemia, particularly in older people (who can be more frail) 129 , which is a common reason for discontinuation of this therapy or for reluctance of HCPs to adjust the basal insulin dose upwards 130,131 .”
Uemura, F., Okada, Y., Mita, T., Torimoto, K., Wakasugi, S., Katakami, N., Yoshii, H., Matsushita, K., Nishida, K., Inokuchi, N., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0465 · Cited by 14 · cited 3×
“…in T2DM and achieve a time below range in hypoglycaemia of 3.0 mmol/l (54 mg/dl) target of 1% of readings each day 40 , it is important that glycaemic variability, as measured by coefficient of variation over the observation period, remains 30% of the mean glucose concentration 39,41 .”
InfluentialFarhan, H., Bukhari, K., Grewal, N., Devarasetty, S., & Munir, K. M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-248579 · Cited by 14
Ajjan, R., Bilir, S. P., Hellmund, R., & Souto, D. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01325-w · Cited by 14 · cited 4×
“Four studies across a range of health-care economies have found that the use of isCGM in people with T2DM on MDI or CSII therapy is considered cost-effective compared with standard care with SMBG, based on a 40-year horizon 137,138,170,171 .”
InfluentialSelf-citationTao, R., Yu, X., Lu, J., Wang, Y., Lu, W., Zhang, Z., Li, H., & Zhou, J. (2023) · Physical and Engineering Sciences in Medicine · doi:10.1007/s13246-023-01254-3 · Cited by 14 · cited 1×
“Following on from these observations, initiatives to use CGM data in artificial intelligence algorithms to more accurately predict the risk of diabetes mellitus complications are underway 100 .”
Is avoidance of hypoglycaemia a better target than HbA1C in older people with diabetes?
Mattishent, K., & Loke, Y. K. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14517 · Cited by 13 · cited 2×
“In this context, deprescribing sulfonylureas is a clear recommendation 148,149 in older people with T2DM, particularly in the presence of comorbidities.”
Uemura, F., Okada, Y., Torimoto, K., & Tanaka, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83999-z · Cited by 13 · cited 2×
“Such treatment profiles could include sulfonylurea therapy in people with T2DM in whom a risk of hypoglycaemia is evident or has been confirmed by CGM 106 , particularly if these people are on higher doses 107 .”
Polonsky, W. H., Soriano, E. C., & Fortmann, A. L. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0526 · Cited by 13 · cited 1×
“…in people with T2DM not on insulin therapy, include: increased hypo-glycaemic confidence, reduced diabetes mellitus distress and better overall wellbeing 79,80 , as well as improved psychological function, diabetes mellitus empowerment and greater diabetes mellitus treatment satisfaction 62,63 .”
Alshannaq, H. A., Pollock, R. F., Joubert, M., Ahmed, W., Norman, G. J., Lynch, P. M., & Roze, S. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0174 · Cited by 13 · cited 2×
“…three national health-care settings showed that using rtCGM in people with T2DM on either MDI or basal insulin therapy is associated with increased QALYs and improved ICER over a lifetime horizon compared with SMBG, based only on direct health-care costs in the UK 172 , Canada 173 or France 174 .”
Diabetes registries and high-quality diabetes care
Khunti, K. K., Mathieu, C., Torbeyns, B., Prato, S. D., Heine, R. J., Colhoun, H. M., Danne, T., Due‐Christensen, M., Eeg-Olofsson, K., Fagherazzi, G., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00386-2 · Cited by 12 · cited 1×
“The importance of digitalization and data registry is emphasized by the European Diabetes Forum 206 and the European Commission 207 .”
Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study
Kaewbut, P., Kosachunhanun, N., Phrommintikul, A., Chinwong, D., Hall, J. J., & Chinwong, S. (2022) · Healthcare · doi:10.3390/healthcare10091673 · Cited by 11
The societal impact of early intensified treatment in patients with type 2 diabetes mellitus
Tsotra, F., Kappel, M., Peristeris, P., Bader, G., Levi, E., Lister, N., Malhotra, A., & Ostwald, D. A. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0110 · Cited by 11
Silva-Tinoco, R., & de la Torre-Saldaña, V. (2021) · Gaceta Médica de México · doi:10.24875/gmm.m21000563 · Cited by 10 · cited 1×
“However, the COVID-19 pandemic has greatly changed the delivery of diabetes mellitus care to emphasize telemedicine in diabetes mellitus consultations 52 , with evidence that telemedicine is not inferior to in-clinic consultations 52,182 .”
CHANG, N. T., Banca, R. O. L., Alula, J. L., Durazo-Arvizú, R., & Chao, L. C. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231178284 · Cited by 10 · cited 1×
“In a pilot randomized crossover trial in nine adolescents aged 15–19 years with a mean HbA 1c of 11.5%, CGM for 3 months was associated with a mean reduction in HbA 1c of 2.8% compared with SMBG 156 .”
Influential
Cited by
Chen, Y., Yang, Z., Liu, Y., Gue, Y. X., Zhong, Z., Chen, T., Wang, F., McDowell, G., Huang, B., & Lip, G. Y. H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02521-7 · Cited by 39
“Continuous glucose monitoring offers a more comprehensive approach, capturing real-time changes and providing better insight into glycemic variability [59].”
Layne, J. E., Jepson, L. H., Carite, A. M., Parkin, C. G., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0197 · Cited by 37
“19 As with glycemic targets, many patient factors may contribute to determining optimal CGM wear cadence and further research may support different recommendations based upon these factors.”
Wang, Y., Lu, J., Yu, J., Ni, J., Wang, M., Lu, W., Zhu, W. M., Guo, J., Bao, Y., & Zhou, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16143 · Cited by 30
Benhalima, K., Durnwald, C. P., Sweeting, A., Adams, D., Addala, A., Battelino, T., Bergenstal, R. M., Carlson, A. L., Donovan, L., Franco, D. R., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00335-3 · Cited by 37
Self-citationAlkabbani, W., CROMER, S. J., Kim, D. H., Paik, J. M., Bykov, K., Munshi, M. N., Wexler, D. J., & Patorno, E. (2025) · Diabetes Care · doi:10.2337/dca25-0006 · Cited by 31
Metadata
- Authors
- Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S.
- Affiliations
- University of Leeds (GB)
- University of Ljubljana (SI)
- Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
- University of Liège (BE)
- Hôpitaux Universitaires de Strasbourg (FR)
- University of Freiburg (DE)
- University of Leicester (GB)
- Corresponding author
- Seidu, Samuel
- ORCID
- Venue
- Nature Reviews Endocrinology
- Published
- 2024-04-08
- Volume
- 20
- Issue
- 7
- Pages
- 426-440
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4394579926
- Cited by
- 117
- References
- 209
- Citations by year
- 2026: 58 · 2025: 48 · 2024: 11
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 2 diabetes, hypoglycemia prevention, treatment intensification, disease progression
- MeSH terms
- Continuous Glucose Monitoring, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.